Last $0.05 USD
Change Today 0.0001 / 0.21%
Volume 26.6K
CORX On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

cortex pharmaceuticals inc (CORX) Snapshot

Open
$0.05
Previous Close
$0.05
Day High
$0.05
Day Low
$0.05
52 Week High
07/2/14 - $0.07
52 Week Low
12/12/13 - $0.02
Market Cap
6.9M
Average Volume 10 Days
34.9K
EPS TTM
$-0.02
Shares Outstanding
144.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORTEX PHARMACEUTICALS INC (CORX)

Related News

No related news articles were found.

cortex pharmaceuticals inc (CORX) Related Businessweek News

No Related Businessweek News Found

cortex pharmaceuticals inc (CORX) Details

Cortex Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The company is involved in developing AMPAKINE compounds, which are novel small molecule compounds that modulate AMPA-type glutamate receptors, a complex of proteins involved in the communication between nerve cells in the mammalian brain. It focuses on the prevention of respiratory depression in post-surgical patients treated with anesthetics, analgesics, or sedatives; and respiratory depression risks related to chronic opioid therapy, without impacting the pain relief provided by the opioids. The company’s lead clinical compounds in Phase II clinical trial comprise CX717 for the treatment of adult patients with attention deficit hyperactivity disorder; and CX1739 for the treatment of sleep apnea. It is also developing AMPAKINE compounds for the treatment of Alzheimer’s disease, mild cognitive impairment, schizophrenia, and depression. The company was formerly known as X-Age, Inc. and changed its name to Cortex Pharmaceuticals, Inc. in August 1988. Cortex Pharmaceuticals, Inc. was founded in 1987 and is based in Glen Rock, New Jersey.

6 Employees
Last Reported Date: 08/16/12
Founded in 1987

cortex pharmaceuticals inc (CORX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cortex pharmaceuticals inc (CORX) Key Developments

Cortex Pharmaceuticals Inc. Announces Resignation of Moogak Hwan from the Board of Directors

On September 30, 2013, Dr. Moogak Hwang notified the Board of Directors of Cortex Pharmaceuticals Inc. of his decision to resign from the Board of Directors effective as of September 30, 2013.

Cortex Pharmaceuticals Inc. Management Changes

On April 29, 2013, Cortex Pharmaceuticals Inc. held a duly noticed telephonic meeting of its Board of Directors in which all directors of the company participated. Among the actions taken by the Board at the meeting, the Board, by unanimous vote, expanded the size of the Board from three to seven and further resolved to fill one of the vacancies created by that expansion, as permitted under the company's Bylaws, with Robert N. Weingarten. Mr. Weingarten was also appointed as a Vice President and the Chief Financial Officer of the Company, to serve until the next annual meeting of the Board of Directors. Mr. Weingarten, is an experienced business consultant and advisor with an ongoing consulting practice. Since 1979 he has provided financial consulting and advisory services to numerous public companies in various stages of development, operation or reorganization. On July 8, 2010, Mr. Weingarten was appointed to the board of directors of Central African Gold Limited.

Cortex Pharmaceuticals Inc. Announces Executive Changes

On March 22, 2013, Cortex Pharmaceuticals Inc. has received an action by written consent of stockholders holding a majority of the company’s common stock signed by Origin Ventures II LP, Illinois Emerging Technologies Fund, LP, Illinois Ventures LLC, Samyang Optics Ltd., Samyang Value Partners Co. Ltd., Steven Chizzik, Kenneth M. Cohen, Peter Letendre, David W. Carley and Aurora Capital LLC (the ‘Written Consent’) (i) removing Charles J. Casamento, Ross Johnson, John F. Benedik and Mark Varney from their positions as directors of the company and (ii) appointing each of Arnold S. Lippa, Ph.D and Jeff E. Margolis to fill the vacancies created, each to hold such office until the next annual meeting of the stockholders and until their successors have been duly elected and qualified. Following the delivery of the Written Consent, the Board of Directors, acting by unanimous written consent dated March 22, 2013, removed all officers of the company and appointed Dr. Lippa, age 66, as Chairman of the Board, President and Chief Executive Officer and Mr. Margolis, age 57, as Vice President, Treasurer and Secretary. Dr. Lippa is a Senior Managing Director and founder of T Morgen Capital LLC through which he administers his family’s assets. Dr. Lippa and Mr. Margolis jointly manage, since 2004, Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life services fund management company and venture fund, respectively.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORX:US $0.05 USD 0.0001

CORX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amorfix Life Sciences Ltd C$0.32 CAD -0.005
Eli Lilly & Co $63.39 USD -0.39
Novartis AG SFr.79.40 CHF -0.55
Pfizer Inc $30.10 USD -0.09
View Industry Companies
 

Industry Analysis

CORX

Industry Average

Valuation CORX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORTEX PHARMACEUTICALS INC, please visit www.cortexpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.